AMAL Therapeutics raises €8mSwiss cancer vaccine developer AMAL Therapeutics has raised €8m in a Series B round led by existing investor Boehringer Ingelheim Venture Fund, and new investors BioMedPartners and Helsinn Investment … more ➔
EU states fuel antimicrobial R&D with... Six European states, together with the Wellcome Trust, and South Africa have pledged €56.5m to help develop new antibiotics that break resistance. more ➔
Smartwatch for patient monitoringResearchers at the University of Sussex have invented a new algorithm that could revolutionise patient monitoring and activity tracking. more ➔
EFSA okays GM bacteria as feed supplementFrench Ajinomoto Eurolysine SAS, part of the world leading producer of amino acids by fermentation, has received a positive safety assessment from the European Food Safety Authority (EFSA) for use of … more ➔
CAR-T: Novartis prices CTL019 at US$475,00...Swiss Novartis AG has received US market authorisation for its first-in-class CAR-T cell therapy Kymriah (tisagenlecleucel-T). As severe cytokine storms seemed to be generally linked to CAR-T therapies … more ➔
FDA approves Boehringers biosimilar adal... The US Food and Drug Administration has granted US market authorisation to Boehringer Ingelheims biosimilar anti-TNFa-antibody adalimumab. more ➔
Apeiron bags €25m from EIB Supported by the European Fund for Strategic Investments (EFSI), the European Investment Bank (EIB) has granted a €25m loan to the Austrian pediatric cancer specialist Apeiron Biologics AG to … more ➔
Implementation of EU Unitary Patent Court... In mid-June, the German Federal Constitutional Court asked the German President not to sign legislation designed to implement the EU Unified Patent Court (UPC, EU Agreement 16351/12) and Unitary … more ➔
Daratumumab meets endpoint as first-line m...Danish Genmab A/S anti-CD38 antibody daratumumab has met the endpoint of progression-free survival in an interim analysis of Genmabs pivotal Phase III study aimed at receiving FDA approval as first-line … more ➔
Macrophage Pharma backed by Merck VenturesMerck Ventures has joined the Series A investor syndicate of the British immuno-oncology specialist Macrophage Pharma Ltd. more ➔
